白蛋白结合型紫杉醇联合卡铂在晚期、复发性上皮卵巢癌治疗中的应用价值

Clinical Researches of Albumin-bound Palliate Combined with Carboplatin for Advanced and Recurrent Epithelial Ovarian Cancer

目的观察白蛋白结合型紫杉醇联合卡铂治疗晚期、复发性上皮卵巢癌的近期疗效和安全性。方法选取86例晚期、复发性上皮卵巢癌患者,随机分成2组。对照组采用溶剂型紫杉醇联合卡铂治疗,观察组采用白蛋白结合型紫杉醇联合卡铂治疗,21天为1个疗程,6个疗程后对治疗的有效性进行评价。结果观察组患者客观缓解率高于对照组(51.16%vs30.23%),差异存在统计学意义(P<0.05),观察组中位生存时间高于对照组(6.8月vs3.6月),死亡例数少于对照组(3例vs5例),差异均有统计学意义(P<0.05)。化疗后,观察组患者生活质量改善率优于对照组(60.47% vs 41.86%),差异有统计学意义(P<0.05)。结论白蛋白结合型紫杉醇联合卡铂治疗晚期、复发性上皮卵巢癌近期疗效较好,不良反应能耐受,值得临床上推广。

Objective To observe the efficacy and safety of albumin-bound palliate combined with carboplatin for ad- vanced and recurrent epithelial ovarian cancer. Methods 86 cases of advanced and recurrent epithelial ovarian cancer were se- lected and randomly divided into 2 groups, The control group was treated with solvent-based palliate combined with carboplatin, the observation group was treated with albumin-bound palliate combined with carbolated drugs ,21 days for a course of treatment, The efficacy of the treatment was evaluated after 6 courses of treatment. Results The rates of objective response in the observa- tion group was higher than that of the control group （51.16%/30.23 % ）, the difference was statistically significant （P 〈 0.05 ）, The time of median survival in the observation group was higher than that of the control group （6.8/3.6 months） , the difference was statistically significant （ P 〈 0.05 ） , After chemotherapy, the improvement rate of quality of life was better in the observation group than that of the control group （60.47%/41.86% ） , the difference was significant （ P 〈 0.05 ）. Conclusion The albumin- bound palliate plus carboplatin as first-line therapy shows favorable benefits and can be well tolerated in patients with advanced and recurrent epithelial ovarian cancer.